QED Therapeutics, BTG, Halozyme, Taiho, and Zymeworks to Present Clinical Trial Concepts to International Research Network

SALT LAKE CITY, UTAH, USA, January 18, 2018 /EINPresswire.com/ -- The Cholangiocarcinoma Foundation (CCF) announced today that five biopharmaceutical companies have been selected to present their clinical trial concepts at the upcoming Annual Conference in Salt Lake City, Utah.

During the Industry Forum event, representatives from QED Therapeutics, BTG, Halozyme, Taiho and Zymeworks will present their clinical trial concepts to the International Cholangiocarcinoma Research Network (ICRN) which represents investigators from 36 medical institutions in 9 countries.

The purpose of the Industry Forum is to accelerate clinical trial development by fostering collaboration between the Foundation and industry partners. “Many global investigators are attending the conference, so it makes sense to invite colleagues from industry to participate and test their concepts. This is one of many ways the Foundation is accelerating development of potential new therapies for patients,” said CCF Executive Director Donna Mayer.

The CCF Conference will be held at the SLC Marriott City Creek January 31 - February 2 and be host to more than 375 attendees representing the medical and scientific communities, industry partners, policy-makers, payers, patients, caregivers and others invested in cholangiocarcinoma.

“We are grateful to QED Therapeutics, BTG, Halozyme, Taiho and Zymeworks for providing educational support for the meeting” shared CCF Founder and President Stacie Lindsey. “Their participation provides a forum to increase the knowledge and understanding of attendees about key issues central to the prevention, diagnosis, treatment, and cure for cholangiocarcinoma.”

Additional funding for this conference was made possible (in part) by a Patient-Centered Outcomes Research Institute Eugene Washington PCORI Engagement Award.

Jordan Giles
Cholangiocarcinoma Foundation
888-396-6731x10
email us here